Haleon plc

LSE HLN.L

Haleon plc EBT Margin for the year ending December 31, 2023: 14.40%

Haleon plc EBT Margin is 14.40% for the year ending December 31, 2023, a -3.33% change year over year. EBT Ratio (Earnings Before Tax Ratio) is the fraction of earnings before taxes to total revenue, indicating the company's profitability before the impact of tax expenses.

Haleon plc EBT Margin for the year ending December 31, 2022 was 14.90%, a -13.06% change year over year.
Haleon plc EBT Margin for the year ending December 31, 2021 was 17.14%, a 6.57% change year over year.
Haleon plc EBT Margin for the year ending December 31, 2020 was 16.08%, a 53.94% change year over year.
Haleon plc EBT Margin for the year ending December 31, 2019 was 10.45%.

Key data

Date	EBT Margin	Net Income Margin	EBITDA Margin	EBIT Margin

LSE: HLN.L

Haleon plc

CEO	Mr. Brian James McNamara
IPO Date	July 18, 2022
Location	United Kingdom
Headquarters	Building 5
Employees	25,408
Sector	Healthcare
Industries Pharmaceuticals Consumer Packaged Goods Cosmetics Dental Care Drugstores & Retail Pharmacies Eyewear Non-Alcoholic Beverages Personal Care

Description

Haleon plc engages in the research and development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides therapeutic oral health, pain relief, respiratory health, digestive health, and other products, as well as vitamins, minerals, and supplements. Its portfolio of brands include Panadol, Voltaren, Advil, Otrivin, Theraflu, Sensodyne, Polident, parodontax, and Centrum. The company was formerly known as DRVW 2022 plc and changed its name to Haleon plc in February 2022. Haleon plc was incorporated in 2021 and is headquartered in Brentford, the United Kingdom.

Key trends

Past 5 years